Pure Global

A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma - Trial NCT05912244

Access comprehensive clinical trial information for NCT05912244 through Pure Global AI's free database. This Phase 2 trial is sponsored by Memorial Sloan Kettering Cancer Center and is currently Recruiting. The study focuses on Melanoma. Target enrollment is 43 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT05912244
Phase 2
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT05912244
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma
A Phase II Study of IO102/IO103 and Nivolumab-relatlimab Fixed Dose Combination in Untreated, Unresectable Stage III/IV Melanoma

Study Focus

Melanoma

IO102/IO103

Interventional

drug

Sponsor & Location

Memorial Sloan Kettering Cancer Center

Basking Ridge,Middletown,Montvale,Commack,Harrison,New York,Uniondale, United States of America

Timeline & Enrollment

Phase 2

Jun 09, 2023

Jun 09, 2027

43 participants

Primary Outcome

Overall Response Rate (ORR)

Summary

The researchers are doing this study to find out whether the study vaccines, IO102/IO103,
 given in combination with the standard-of-care drug combination, nivolumab and relatlimab, is
 a safe and effective treatment for people with untreated, unresectable melanoma.

ICD-10 Classifications

Malignant melanoma of skin
Melanoma in situ, unspecified
Melanoma in situ
Melanoma and other malignant neoplasms of skin
Malignant neoplasm: Malignant melanoma of skin, unspecified

Data Source

ClinicalTrials.gov

NCT05912244

Non-Device Trial